| Identification | Back Directory | [Name]
EIDD-2801 | [CAS]
2349386-89-4 | [Synonyms]
Tube994
EIDD-2801
EIDO-2801
Molnupiravir
UNII-YA84KI1VEW
Molnupiravir-001
EIDD-2801(EIDD 2801)
Molnupiravir(MK-4482)
EIDD-2801(Molnupiravir)
Molnupiravir(EIDD-2801）
MolnupiravirEIDD-2801(API)
Uridine, 4-oxime, 5'-(2-methylpropanoate)
β-D-N4 hydroxycytidine-5'-isopropyl ester
((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-(hydroxyamino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C13H19N3O7 | [MOL File]
2349386-89-4.mol | [Molecular Weight]
329.31 |
| Chemical Properties | Back Directory | [Melting point ]
156 - 159°C | [storage temp. ]
-20°C, Inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
White to Off-White | [InChI]
InChI=1/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/s3 | [InChIKey]
HTNPEHXGEKVIHG-JFPRWSRANA-N | [SMILES]
O[C@@H]1[C@@H]([C@@H](COC(=O)C(C)C)O[C@H]1N1C=C/C(=N/O)/NC1=O)O |&1:1,2,3,12,r| |
| Hazard Information | Back Directory | [Description]
EIDD-2801 is an orally bioavailable prodrug of the antiviral nucleoside derivative N4- hydroxycytidine (NHC, EIDD-1931). It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase. It exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. The broadspectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) and coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2. EIDD-2801 has the potential for COVID-19, seasonal and pandemic influenza treatment. | [History]
Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission, as well as SARS-CoV-1 and MERS. EIDD-2801 was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-prot biotechnology company wholly owned by Emory University, and with partial funding support from the U.S. government. Since licensed by Ridgeback, all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck. | [Uses]
EIDD 2801 is an orally bioavailable broad-spectrum antiviral that inhibits SARS-CoV-2 and other multiple endemic, epidemic and bat coronavirus and has the potential for seasonal and pandemic influenza treatment. An isopropylester prodrug of the ribonucleoside analog of EIDD-1931 that exhibits anti-influenza virus and coronaviruses activities. | [Definition]
Molnupiravir is a nucleoside analogue that is N(4)-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N(4)-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19. It has a role as a prodrug, an anticoronaviral agent and an antiviral drug. It is a nucleoside analogue, an isopropyl ester and a ketoxime. It derives from a N(4)-hydroxycytidine.
www.ebi.ac.uk | [Biological Activity]
EIDD-2801 is an orally active, 5′-isopropylester prodrug form of the antiviral ribonucleoside analog N4-hydroxycytidine (NHC, EIDD-1931) with known anti-viral activity against SARS-CoV, SARS-CoV-2, RSV, influenza A & B (IAV & IBV), HCV, pestivirus, bovine viral diarrhoea virus (BVDV), Ebola (EBOV), Chikungunya (CHIKV), venezuelan equine encephalitis (VEEV). EIDD-2801 is efficiently hydrolyzed to NHC in vivo, being more orally bioavailable than NHC in nonhuman primates and ferrets, while maintaining similar oral bioavailability as NHC in mice. EIDD-2801 displays in vivo efficacy against pandemic and seasonal IAV strains in ferrets (lowest ED = 2.3 and 7 mg/kg b.i.d. p.o., respectively). | [Synthesis]
The synthesis of molnupiravir starts from uridine and is synthesized in five steps. The specific synthetic route is as follows: the two secondary alcohols (3.1) in uridine are protected to acetonide (acetonide) using 2,2-dimethoxypropane in acetone under the action of sulfuric acid catalysis. Dynamic crystallization, quenching with triethylamine, and subsequent addition of n-heptane gave the acetonide product in 91% yield on a metric ton scale. The 5′-isobutyryl group is then introduced (using isobutyric anhydride, triethylamine, 4-dimethylaminopyridine, and ethyl acetate) to generate the ester 3.2, which is processed in the form of an acetonitrile solution. The solvent switch from ethyl acetate to acetonitrile eliminates the risk of product precipitation during storage and slightly increases the reaction rate of the subsequent steps. The C4 carbonyl of the uracil ring on the intermediate 3.2 is converted to the corresponding oxime (3.4) in two steps. The amide carbonyl is first activated using a triazole phosphate reagent generated in situ from 1,2,4-triazole, diisopropylethylamine, and phosphorus trichloride in acetonitrile. Due to the nucleophilicity of 1,2,4-triazole at both N1/N2 (desired position) and N4 (undesired position), a mixture of triazole isomers was generated initially in the reaction, but in the presence of excess triazole, it was converted to the thermodynamically more stable desired isomer (ratio >99:1) within a few hours. Crystallization using water as an antisolvent provided the triazole intermediate 3.3 in 92% yield over a two-step process. Subsequent workup included treatment with water-soluble hydroxylamine and crystallization directly after addition of water to afford the final oxime 3.4 in 91% yield. Finally, removal of the acetonide protecting group under acidic conditions (HCl, water, and MeCN) afforded Molnupiravir (3). This deprotection step required extensive optimization to minimize hydrolysis of the acid-sensitive ester and oxime functionalities. The final active pharmaceutical ingredient was crystallized by slow addition of ethyl acetate to obtain a high purity product in 76% overall yield (57% from uracil in 5 steps).
 | [Mode of action]
Molnupiravir (development codes MK-4482 and EIDD-2801) is an investigational antiviral drug, which is the orally-bioavailable prodrug of the ribonucleoside analog N4-hydroxycytidine (NHC, EIDD-1931) that inhibits the replication of multiple RNA viruses, including SARS-CoV-2, by introducing copying errors during viral RNA replication. EIDD-1931 has broad spectrum antiviral activity against influenza virus and coronaviruses, such as MERS-CoV, and SARS-CoV.
Molnupiravir attacks the same viral enzyme as Gilead’s Remdesivir, but it can be taken orally. This would allow an administration at home and, therefore, earlier in the course of the disease. According to Ridgeback Biotherapeutics, Molnupiravir has an extremely high barrier to resistance.
According to MSD, Molnupiravir is aimed at the treatment of Covid-19 in
patients hospitalized due to mild, moderate or severe disease,
non-hospitalized patients with mild or moderate disease | [Preparation and handling]
Molnupiravir is supplied as a crystalline solid. A stock solution may be made by dissolving molnupiravir in the solvent of choice, which should be purged with an inert gas. Molnupiravir is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of molnupiravir in these solvents is approximately 30 mg/ml.
Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of molnupiravir can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of molnupiravir in PBS, pH 7.2, is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day. | [Regulatory Status]
Molnupiravir (as EIDD-2801) was developed at Drug Innovation Ventures at Emory (DRIVE), a not-forprofit biotechnology company owned by Emory University, Atlanta. It was then licensed by Ridgeback Biotherapeutics, and is now developed further in cooperation with Merck & Co. (in Europe: Merck Sharp & Dohme/ MSD).
Molnupiravir is not approved by the European Medicines Agency (EMA) or the American Food and Drug Administration (FDA). | [References]
[1] Toots M, Yoon J-J, Cox RM et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science Translational Medicine 2019;11(515). Epub 23 Oct 2019.
[2] Toots M, Yoon J-J, Hart M et al. . Quantitative Efficacy Paradigms of the Influenza Clinical Drug Candidate EIDD-2801 in the Ferret Model. Transl Res 2020. Epub 2019 Dec 25.
[3] Halford B. An emerging antiviral takes aim at COVID-19. American Chemical Society; 2020 [14.12.2020]; Available from: https://cen.acs.org/pharmaceuticals/drug-development/emergingantiviral-takes-aim-COVID-19/98/web/2020/05.
[4] Ridgeback Biotherapeutics. OVERVIEW OF EIDD-2801 (MK-4482). [Presentation]. provided via email 2020. |
|
| Company Name: |
Acesys Pharmatech
|
| Telephone: |
18860950986 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15849/0_EN.htm |
|